Treatment with Teva Pharmaceutical Industries Limited (TEVA)'s COPAXONE(R) in Multiple Sclerosis Demonstrated Remyelination and Neuroprotective Effects in a Preclinical Setting
10/20/2011 10:10:38 AM
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced preclinical data demonstrating reparative and neuroprotective effects of treatment with COPAXONE® (glatiramer acetate injection) in experimental autoimmune encephalomyelitis (EAE) models. In the study, researchers compared mice treated with COPAXONE® versus non-treated mice in relapsing-remitting and chronic multiple sclerosis (MS) disease models. Researchers observed both remyelination indicative of repair and a drastic reduction of demyelination and axonal loss in mice treated with COPAXONE®.